STOCK TITAN
  1. Home
  2. News
  3. VTRLY

Vitrolife AB - VTRLY STOCK NEWS

Welcome to our dedicated news page for Vitrolife AB (Ticker: VTRLY), a resource for investors and traders seeking the latest updates and insights on Vitrolife AB.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Vitrolife AB's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Vitrolife AB's position in the market.

News
Interim report Q1, 2024: Strong growth in APAC and solid margins
Rhea-AI Summary
Vitrolife AB (publ) reported a first-quarter sales of SEK 841 million with flat growth in local currencies but a 2% decrease in SEK. Sales in APAC grew by 19%, while EMEA and Americas saw declines. Gross margin increased to 57.1%, EBITDA margin to 32.4%, and operating cash flow to SEK 198 million. Net income rose to SEK 115 million. The company restructured its business areas, with Genomics now part of Genetics. CEO Bronwyn Brophy O´Connor highlighted strong growth in APAC and solid margins.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Correction: Notice to attend the Annual General Meeting of Vitrolife AB (publ)
Rhea-AI Summary
Vitrolife AB (VTRLY) announces its Annual General Meeting for April 25, 2024, with key agenda items such as election of auditors and approval of financial reports. Shareholders must register by April 19, 2024, and can vote via postal or electronic means. The company proposes a dividend of SEK 1.00 per share and discusses the appointment of Board members, remuneration, and auditors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Conference call interim report
Rhea-AI Summary
Vitrolife AB (publ) invites you to attend a conference call for the presentation of their Q1 2024 interim report. The call will be in English on April 18, 2024, at 10.00 a.m. CET. Registration required. The press release will be available at 8.00 CET on the same day. Recorded conference available for seven days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Vitrolife Group Annual and Sustainability Report 2023
Rhea-AI Summary
Vitrolife Group has released its Annual and Sustainability Report for 2023, available digitally in English and Swedish. The report follows the European Single Electronic Format (ESEF) and can be requested in print. Vitrolife AB (publ) complies with Swedish Securities Markets Act disclosure requirements.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Notice to attend the Annual General Meeting of Vitrolife AB (publ)
Rhea-AI Summary
Vitrolife AB (VTRLY) announces Annual General Meeting with dividend proposal and board member re-election. Shareholders must register by April 19, 2024, and vote on various proposals including dividend payout, board composition, and auditor re-appointment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
-
News
Vitrolife AB (publ): Fourth quarter and full year report, 2023; continued growth with margin expansions
Rhea-AI Summary
Vitrolife AB (publ) reported a 6% increase in fourth quarter sales to SEK 904 million, with sales in local currencies growing by 5%. Sales in APAC and EMEA increased by 16% and 6%, respectively, while sales in the Americas decreased by 5%. The company reported an impairment charge of SEK 4,300 million, resulting in a net income of SEK -4,179 million. Excluding the impairment charge, net income increased to SEK 121 million. Full-year sales increased by 9% to SEK 3,512 million, with a gross margin of 56.3%. The company proposed a dividend of SEK 135 million, excluding the non-cash impairment charge.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Vitrolife AB (publ): Conference call full year report 2023
Rhea-AI Summary
Vitrolife AB (VTRLY) invites to a conference call for the presentation of the fourth quarter and full year report 2023. The call will be held in English on February 2, 2024, at 10.00 a.m. CET. The press release for the full year report will be released at 8.00 CET on the same day. Participants include CEO Bronwyn Brophy O´Connor and CFO Patrik Tolf. The recorded version of the telephone conference will be available for seven days.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vitrolife Group unveils new corporate strategy and updates long-term financial objectives at Capital Markets Day
Rhea-AI Summary
Vitrolife AB (publ) (VITR.ST) is hosting a Capital Markets Day presentation in Stockholm, Sweden, to present its new corporate strategy focused on reproductive health. The company aims to achieve long-term, sustainable, profitable growth through innovation, expansion in key markets, and operational excellence. Vitrolife Group also plans to double its investment in R&D, increase capabilities in the US and China, and drive automation and digitalization across the business.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Vitrolife Group to host Capital Markets Day on 12 December 2023
Rhea-AI Summary
Vitrolife AB (publ) will host a Capital Markets Day presentation on 12 December 2023, featuring CEO Bronwyn Brophy and CFO Patrik Tolf, along with experts in the reproductive health industry. The event will focus on the future of infertility care and the company's new corporate strategy for sustainable, profitable growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
News
Vitrolife AB (publ) - Interim report Q3, 2023: Profitable growth globally despite headwind in the U.S.
Rhea-AI Summary
Vitrolife AB (publ) reports Q3 sales growth of 6% and operating income increase. Gross margin and operating cash flow also improved. However, Americas sales decreased by 8%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.02%
Tags
none
Stock VTRLY logo
Vitrolife AB

OTC:VTRLY

VTRLY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

VTRLY Stock Data

2.23B
75.00M
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
Sweden
Goteborg